Critical Survey: 908 Devices (NASDAQ:MASS) and Vaso (OTCMKTS:VASO)

Vaso (OTCMKTS:VASO) and 908 Devices (NASDAQ:MASS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Valuation and Earnings

This table compares Vaso and 908 Devices”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaso	$86.77 million	0.35	$950,000.00	$0.01	17.40
908 Devices	$59.63 million	3.98	-$72.21 million	($0.11)	-59.64

Vaso has higher revenue and earnings than 908 Devices. 908 Devices is trading at a lower price-to-earnings ratio than Vaso, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Vaso and 908 Devices, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaso	0	0	0	0	0.00
908 Devices	1	0	1	0	2.00

908 Devices has a consensus price target of $12.00, indicating a potential upside of 82.93%. Given 908 Devices’ stronger consensus rating and higher possible upside, analysts clearly believe 908 Devices is more favorable than Vaso.

Profitability

This table compares Vaso and 908 Devices’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaso	2.91%	9.49%	3.16%
908 Devices	-7.17%	-22.31%	-16.90%

Institutional and Insider Ownership

88.1% of 908 Devices shares are owned by institutional investors. 43.9% of Vaso shares are owned by insiders. Comparatively, 23.7% of 908 Devices shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Vaso has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, 908 Devices has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

Summary

Vaso beats 908 Devices on 8 of the 14 factors compared between the two stocks.

About Vaso

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.

About 908 Devices

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.